Long non-coding RNAs: Key regulators in oxaliplatin resistance of colorectal cancer - 18/06/20
páginas | 10 |
Iconografías | 3 |
Vídeos | 0 |
Otros | 0 |
Highlights |
• | Identification of 8 lncRNAs involved in oxaliplatin resistance of colorectal cancer. |
• | Long noncoding RNAs have 4 mechanisms of oxaliplatin resistance in colorectal cancer. |
• | Clinical application of long noncoding RNAs as biomarkers and therapeutic targets. |
Abstract |
Colorectal cancer (CRC) is one of the most commonly diagnosed malignancies in the world with high relapse and mortality rates. Although oxaliplatin (OXA), a platinum-based anticancer drug, is widely used in CRC treatment, the resulting chemoresistance dramatically attenuates the drug efficacy and increases the failure rate of this therapy. Thus, the study on OXA-induced chemoresistance is extremely urgent. In recent years, emerging evidence has shown that lncRNAs play irreplaceable roles in drug resistance. However, we only have a limited knowledge of the lncRNAs that are closely related to oxaliplatin resistance in CRC. In present study, we identify and characterize these lncRNAs, including their functions, underlying mechanisms and possible applications.
El texto completo de este artículo está disponible en PDF.Keywords : Long non-coding RNA, Oxaliplatin, Colorectal cancer, Chemoresistance
Esquema
Vol 128
Artículo 110329- août 2020 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
La compra de artículos no está disponible en este momento.
¿Ya suscrito a @@106933@@ revista ?